Numerous data from published reports prove that the proliferation of gastrointestinal tumour cell lines are under the control of many hormones or growth factors, or both. Most of these publications report the influence on a very small number of cell lines of one or two such factors only. This work deals with the in vitro characterisation of the influence of the anti-gastrin, the anti-epidermal growth factor (EGF), the anti-oestradiol (E2), and the anti-luteinising hormone releasing hormone (LHRH) antibodies on the proliferation of a large series of gastrointestinal cell lines. Cell proliferation was assessed by means of the colorimetric MTT assay on a series of 27 gastrointestinal cell lines obtained from the American Type Culture Collection (ATCC). Of the 27 cell lines, the antiastrin, the anti-EGF, the anti-E2, and the anti-LHRH neutralising antibodies considerably influenced the proliferation of 13, 25, 12, and 16. No gastrointestinal cell line was unresponsive to the four antibodies simultaneously. The anti-gastrin and anti-EGF antibody induced effects on the 27 gastrointestinal cell line proliferation were significantly correlated, as was also the case for the anti-E2 and anti-LHRH antibody induced effects. Of the anti-gastrin, the anti-EGF, the anti-E2, and the anti-LHRH antibodies, it was the anti-EGF one that had the greatest influence, both quantitatively and qualitatively, on gastrointestinal cell proliferation. The correlation of the effects of definite anti-hormone antibodies is suggestive of a common mechanism of action for the corresponding hormones and casts some doubt on the efficiency of anti-hormone monotherapy. (Gut 1995; 36:220-230) 
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It has become clearly established that gastrin plays an important part in the growth control of normal and malignant gastrointestinal mucosal4 since the description of the presence of gastrin receptors in rats' stomachs.5 This role is mediated through the gastrin receptors6-9 and is exerted by an autocrine action mechanism.1012 Furthermore, recent data show that gastrointestinal tumour cells, and especially colorectal ones, are also sensitive to hormones or growth factors, or both like the transforming growth factors alpha and beta,'3-16 the insulin like growth factors I and II,13 17 the basic fibroblast growth factor,18 and many others. In addition to these growth factors two additional ones are also well known as stimulants of gastrointestinal cell line proliferation. These are oestradiol (E2)19-21 and the epidermal growth factor (EGF), 2223 for both of which specific receptors exist in normal and neoplastic gastrointestinal mucosa.14 [24] [25] [26] We recently showed that the luteinising hormone releasing hormone (LHRH) can also considerably modulate colorectal cell proliferation.21
Referring to the results contained in published works, Frucht et al 27 state that they are limited because it often happens that only a small number of tumours are studied, only one or two receptors are sought, and the effect on cell function is not investigated. In their study of 10 recently characterised human colon cancer cell lines undertaken to discover if they possessed receptors for any of 12 different gastrointestinal hormones or neurotransmitters, these authors27 show on these cell lines the presence of several different receptors that are functional because occupation by selective agonists has changed the intracellular mediators. While they27 consider it necessary to extend their studies to evaluate growth effects, we have taken this as the goal of this work, which deals with the in vitro characterisation of the influence of the gastrin, the EGF, the E2, and the LHRH on the proliferation of 27 gastrointestinal cell lines obtained from the American Type Culture Collection (ATCC).
We preferred to add the anti-hormone or antigrowth factor antibody, or both in the culture medium rather than the hormone or growth factor itself because more information is available in this way. Indeed, a significant hormone or growth factor induced effect, or both on a given cell line proliferation shows that the proliferation of this cell line is 'sensitive' to the addition of this hormone or growth factor, but does not show if such proliferation was already under the influence of this hormone or growth factor present in the medium or secreted by autocrine or paracrine mechanisms, or both. It should be emphasised that these antibodies would not cross the cell membrane and therefore, if there are intracrine mechanisms linked with some of these hormones, then these antibodies would not affect such a mechanism.
Cell proliferation was assessed by means of the colorimetric MTT assay.28-30
Methods

CELLS AND MEDIUM
All the 27 gastrointestinal cell lines were obtained from the ATCC (Rockville, MD). (Gibco) .
All the mediums were supplemented with a mixture of 0-6 mg/ml glutamine (Gibco), 200 IU/ml penicillin (Gibco), 200 ,ug/ml streptomycin (Gibco), and 01 mg/ml gentamycin (Gibco). The 
tetrazolium bromide, Sigma) at 1 mg/ml RPMI medium (Seromed, Berlin, Germany). The plates were incubated for three hours at 37°C and then centrifuged for seven minutes at 400 g. The medium was replaced with 100 ,ul dimethylsulphoxide (DMSO). The multiwells were shaken on a plate shaker for 10 minutes; they were then read on a Bio-Tek Instrument Microplate Reader (EL 308) using a test wavelength of 570 nm and a reference one of 630 nm. 28 The cells were incubated in an antihormone or anti-growth factor antibody-free medium, for 24 hours in each experimental condition to ensure good plating conditions.
In each experiment the various cell lines were incubated for 72 hours (after the 24 hour plating procedure) in either an anti-hormone or an anti-growth factor antibody-free medium, or both (control), or one supplemented either with 50 ng/ml (0.33 nM), 500 ng/ml (3.3 nM), 5000 ngfml (33 nM), or 10 000 ng/ml (67 nM) of each of the four antibodies under study -that is, the antigastrin (polyclonal A568 rabbit antibody, Dakko, Trappes, France), the anti-EGF (monoclonal MAB 126 mouse antibody, Euromedex, Schiltgheim, France), the anti-E2 (monoclonal MAB 1233 mouse antibody, Euromedex), and the anti-LHRH (polyclonal AB923 rabbit antibody, Euromedex) antibody.
All the assays were performed in sextuplicate. We have chosen to base our argument on the effect brought about by the maximum dose of the antibody tested here -that is, 10 000 ng/ml -because we consider that this is the dose which were highly sensitive to these hormones. however, that of the 16 theoretical phenotypes only some were experimentally observed. Furthermore, Table II also shows that some of these experimentally observed phenotypes were seen more frequently than others. The theoretical phenotypes not experimentally seen were the HI, the gastrin, the gastrin/E2, the gastrin/LHRH, the E2/LHRH, the gastrin/EGF/E2, and _ the gastrinlE2/LHRH. In sharp contrast, the 60 experiments showed that of the remaining nine phenotypes three were seen predominantly. These were the gastrin/EGF, the EGF/E2/LHRH, and the gastrin/ EGF/E2/LHRH. The other six phenotypes, the EGF, the E2, the LHRH, the EGF/E2, the EGF/LHRH, and the gastrin/EGF/LHRH, were characterised between one and three cell lines of the 27 under study. This experimental absence of some theoretical phenotypes and the presence of some other predominant ones led us to try to find a possible statistically significant relation between the combined effect of some of the hormones or growth factors under study. Figure 8 and Table III shows the results. Table III shows that the anti-gastrin antibody induced effect on the proliferation of the 27 cell lines at the 10 000 ng/ml and 500 ngfml doses was highly correlated with those of the anti-EGF antibody. A statistically significant 60 effect was also seen with the 5000 ng/ml dose but not with the 50 ng/ml one (data not shown). In the same way, the anti-E2 antibody induced effect on the proliferation of the 27 cell lines correlated significantly with that of the anti-LHRH effect. This effect was more noticeable at the 5000 (data not shown) and 500 ng/ml doses than at the 10 000 ng/ml one. No statistically significant relation was seen at the 50 ng/ml dose (data not shown). dots correspond to the effects recorded at the 500 ng/ml dose. It seems that such relations are linear and positive and are more pronounced between the anti-gastrin and anti-EGF antibodies than between the anti-E2 and anti-LHRH ones.
Lnd
Discussion
In a study (unpublished data) we describe the influence of various anti-hormone or antigrowth factor antibodies on the proliferation of two human neoplastic colorectal cell lines, the LoVo and HCT-15 cells. The data show that of the 19 antibodies tested, 10 modified the in vitro proliferation of these two cell lines very significantly. These 10 antibodies were the anti-insulin like growth factor I, the anti-transforming growth factor alpha, the anti-basic fibroblast growth factor, the anticarcinoembryonic antigen, the anti-prolactin, the anti-platelet derived growth factor, the anti-gastrin, the anti-EGF, the anti-E2, and the anti-LHRH antibodies. As for the remaining nine antibodies in this study (the antitransforming growth factor beta, the antitumour necrosis factors alpha and beta, the anti-bombesin, the anti-nerve growth factor, the anti-substance P, the anti-secretin, the anti-somatostatin, and the anti-vasoactive intestinal peptide antibodies), we were not able to show any really significant influence on LoVo and HCT-15 cell proliferation.
To test the clinical relevance of these data we decided to continue our experiment with an investigation into the effect on a large series of gastrointestinal cell lines of anti-hormone or anti-growth factor antibodies known to have a considerable influence on the proliferation of the LoVo and the HCT-15 cell lines. This is the aim of this study, which characterises the influence of the anti-gastrin, anti-EGF, anti-E2, and anti-LHRH antibodies on the proliferation of 27 gastrointestinal cell lines.
The methodology used here is unusual. Indeed, it was the anti-hormone or anti-growth factor antibody rather than the hormone or growth factor itself that was used to characterise the hormone sensitivity profile of the gastrointestinal cell line under consideration. We used this methodology because our laboratory has been able to observe some very considerable interference in the field of cell proliferation between the effect of the hormone added exogeneously to the culture medium and that of the hormone existing endogeneously in the same medium. This finding, made over a number of years, is based on a very large number of experimental models. Our present argument is wholly based on the opinion that the addition of the antibody to the culture medium will inhibit the biological activity of the hormone or the growth factor targeted and that the most effective inhibition of this biological activity is obtained at the highest concentration used here, namely 10 000 ng/ml. In other words, we believe that a concentration of 10 000 ng/ml provides the best mirror image of what the influence of the hormone or growth factor would have been at an equivalent concentration. We could not test any higher antibody concentrations because of the cost of the experiments.
It should also be emphasised that we preferred to use the anti-hormone or anti-growth factor antibody rather than the hormone or growth factor itself because more information becomes available in this way. Indeed, a positive effect of hormones or growth factors added to the medium is evidence of sensitivity of the tumour cells to the hormone or growth factor tried, but it does not provide any information on the possible action of the same hormone or growth factor on cultures growing in unsupplemented medium. The influence of neutralising antibodies on growth of the culture is proof that the cell lines were already stimulated by the corresponding hormone or growth factor, either present in the fetal calf serum used in the medium, or secreted by an autocrine or paracrine mechanism, or both by the tumour cells themselves.
It should also be emphasised that this study assessed the proliferation rate by means of the recently criticised50'52 colorimetric assay.28 30 We maintain that we really did measure the cell proliferation rate by means This study shows that there were 16 theoretical hormone sensitive phenotypes that could exist given the fact that four hormones or growth factors were used; of these only nine were present, and of these nine, three predominated. These facts strongly suggest that coregulating phenomena with respect to gastrointestinal cell proliferation occur between the four hormones or growth factors under study. By way of an example, none of the 27 gastrointestinal cell lines under study seemed to be sensitive to the gastrin only, as was also the case with the E2+LHRH. Moreover, the gastrin/E2, the gastrin/LHRH, and the gastrin/E2/LHRH do not exist. Everything suggests that the gastrin and E2+LHRH would act as independent regulators of the in vitro gastrointestinal cell proliferation. In addition to these two independent regulators, the EGF seems to constitute a third regulator that is not independent of the other two, but more the dominant partner. However, the gastrin/EGF/E2 phenotype does not exist. It thus seems impossible to see a noticeable and concomitant gastrin and E2 induced stimulation of the gastrointestinal cell proliferation. These two hormones seem to be mutually exclusive with respect to their action on the gastrointestinal cell proliferation. This feature might be related to up and down regulation phenomena exerted by the gastrin and E2 at the level of their secretion or receptor expression, or both. 55 56 While the results show that the effects of certain hormones or growth factors can be correlated with the proliferation of the neoplastic gastrointestinal cells, they also raise the problem of the possible effectiveness of mono-hormonotherapy on this type of cancer. In fact, antagonising the biological activity of a hormone by the use of an antagonist is not wholly inconceivable. This is true for tamoxifen and oestradiol in the case of breast cancers. These results strongly suggest that, in the case of the projected treatment of colorectal cancer by hormonotherapy, there would be an immediate need for polyhormonotherapy including at least gastrin, oestradiol, and LHRH antagonists because otherwise the hormone whose effect had not been antagonised at proliferation level might replace the other one. In the same way, it seems that the use of a gastrin antagonist alone would not be enough to inhibit the proliferation of neoplastic gastrointestinal cells sensitive to it as the EGF is more than likely to take over. Experiments are being carried out in the laboratory to investigate the effect of various combinations between the anti-gastrin, the anti-E2, and the anti-LHRH antibodies on the gastrointestinal cell line proliferation. The results show that most of the antihormone or anti-growth factor antibodies induced a dose dependent effect on the gastrointestinal cell proliferation. This was the case with respect to the anti-EGF antibody on the GPC-1 6 cell line (Fig 2) and to the anti-LHRH antibody on the NCI-H508 one (Fig 4) . In contrast, some intermediate situations were also seen. For example, this was the case with respect to the SW403 cell line, where the anti-gastrin, the anti-EGF, and the anti-E2 antibodies induced an increase and not a decrease in cell proliferation (Fig 1) . This was also seen with respect to the effect of the anti-E2 antibody on SW1463 (Fig 1) and LS180 (Fig 5) cell proliferation. It was also seen that a given antibody induced a potent inhibition of cell proliferation at a high dose but a stimulation of the same cell proliferation at a lower one. This was the case with the effects of the anti-LHRH antibody on SW403 cell proliferation (Fig 1) , of the anti-EGF antibody on CoLo32ODM proliferation (Fig 2) , and of the anti-E2 antibody on the CoLo205 (Fig 4) .
We think that such antibody induced rebound effects might be partly explained by the fact that the hormones or the growth factor may exert a dual influence on the proliferation of some cancers. This dual influence corresponds to a stimulating influence on cell proliferation accompanied by an increase in mitoses, and to an inhibitory one accompanied by an increase in apoptosis. Such dual hormone or growth factor induced effects on cell proliferation are described in several experimental models related to the liver,57 the MXT mouse mammary carcinoma,58 the uterus,59 and the prostate.60
In conclusion, we believe that when the antibody brings about a significant decrease in cell proliferation when tested at the highest concentration, this corresponds to the elimination of the mitogeneous activity of the hormone or the growth factor. In contrast, we believe that when a lower concentration of this antibody brings about an increase in cell proliferation, this corresponds to the elimination of a part of the hormone or growth factor induced apoptosis related cell death effect. As the cell lines proliferate very rapidly in vitro (and never regress spontaneously), it is logical for us to have seen that while the mitogeneous biological activity of a hormone or growth factor is associated with large amounts of the antibody, the biological activity connected with the apoptosis entails smaller amounts. We are in the process of testing this hypothesis by means of biochemical (endonuclease activation) and electron microscopy (search for apoptotic bodies) experiments.
These data characterised the influence of the anti-gastrin, the anti-EGF, the anti-E2, and the anti-LHRH antibodies on the proliferation of 27 gastrointestinal cell lines and show that it was the anti-EGF neutralising antibody that had the greatest (93%) and the most noticeable influence on the gastrointestinal cell line proliferation. In contrast, the anti-E2, the anti-gastrin, and the anti-LHRH neutralising antibodies had a real influence on only about half of the gastrointestinal cell proliferation. Thus, the gastrin was not the major regulator of the gastrointestinal cell line proliferation. The antigastrin and anti-EGF antibody induced effects on the 27 gastrointestinal cell line proliferation were significantly correlated, as was also the case for the anti-E2 and anti-LHRH antibody induced effects. Lastly, none of the gastrointestinal cell lines was totally hormone insensitive and in view of the fact that four anti-hormone or anti-growth factor antibodies were used in this study, 16 theoretical hormone sensitive phenotypes were possible but only nine were experimentally seen. Of these nine phenotypes, three were predominant. These were defined as the gastrin/EGF, the EGF/E2/LHRH, and the gastrinlEGF/E2/LHRH and showed that the gastrointestinal cell lines exhibited an equal degree of sensitivity to gastrin+EGF, EGF+E2+LHRH, and to gastrin+EGF+ E2 +LHRH.
Additional experiments are currently under way in the laboratory to characterise the biochemical transduction pathway used by these various anti-hormone or anti-growth factor antibodies.
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